Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis

From BugSigDB
Needs review
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Wen C, Zheng Z, Shao T, Liu L, Xie Z, Le Chatelier E, He Z, Zhong W, Fan Y, Zhang L, Li H, Wu C, Hu C, Xu Q, Zhou J, Cai S, Wang D, Huang Y, Breban M, Qin N, Ehrlich SD
Journal
Genome biology
Year
2017
BACKGROUND: The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing spondylitis is an inflammatory autoimmune disease and evidence showed that ankylosing spondylitis may be a microbiome-driven disease. RESULTS: To investigate the relationship between the gut microbiome and ankylosing spondylitis, a quantitative metagenomics study based on deep shotgun sequencing was performed, using gut microbial DNA from 211 Chinese individuals. A total of 23,709 genes and 12 metagenomic species were shown to be differentially abundant between ankylosing spondylitis patients and healthy controls. Patients were characterized by a form of gut microbial dysbiosis that is more prominent than previously reported cases with inflammatory bowel disease. Specifically, the ankylosing spondylitis patients demonstrated increases in the abundance of Prevotella melaninogenica, Prevotella copri, and Prevotella sp. C561 and decreases in Bacteroides spp. It is noteworthy that the Bifidobacterium genus, which is commonly used in probiotics, accumulated in the ankylosing spondylitis patients. Diagnostic algorithms were established using a subset of these gut microbial biomarkers. CONCLUSIONS: Alterations of the gut microbiome are associated with development of ankylosing spondylitis. Our data suggest biomarkers identified in this study might participate in the pathogenesis or development process of ankylosing spondylitis, providing new leads for the development of new diagnostic tools and potential treatments.

Experiment 1


Needs review

Curated date: 2023/03/15

Curator: Ufuoma Ejite

Revision editor(s): Ufuoma Ejite

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled (if applicable)
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
ankylosing spondylitis Ankylosing Spondylarthritides,Ankylosing Spondylarthritis,ankylosing spondylitis,Ankylosing Spondyloarthritides,Ankylosing Spondyloarthritis,BECHTEREW DIS,Bechterew Disease,Bechterew's Disease,BECHTEREWS DIS,Bechterews Disease,Bekhterev syndrome,Bekhterev's disease,MARIE STRUEMPELL DIS,Marie Struempell Disease,Marie-Struempell Disease,Marie-Strumpell disease,Rheumatoid Spondylitis,Spondylarthritides, Ankylosing,Spondylarthritis Ankylopoietica,Spondylarthritis, Ankylosing,Spondylitis, Ankylosing,Spondylitis, Rheumatoid,Spondyloarthritides, Ankylosing,Spondyloarthritis, Ankylosing
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy controls
Group 1 name Corresponds to the case (exposed) group for case-control studies
Ankylosing spondylitis patients
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Ankylosing spondylitis confirmed by calculating the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Group 0 sample size Number of subjects in the control (unexposed) group
114
Group 1 sample size Number of subjects in the case (exposed) group
97
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
4 weeks

Lab analysis

Sequencing type
WMS
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
Mann-Whitney (Wilcoxon)
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.001


Alpha Diversity

Shannon Estimator of species richness and species evenness: more weight on species richness
decreased
Simpson Estimator of species richness and species evenness: more weight on species evenness
decreased
Richness Number of species
decreased

Signature 1

Needs review

Curated date: 2023/03/15

Curator: Ufuoma Ejite

Revision editor(s): Ufuoma Ejite

Source: Figure 1a

Description: Differences of phylogenetic abundance between AS patients and healthy controls

Abundance in Group 1: increased abundance in Ankylosing spondylitis patients

NCBI Links
Bifidobacterium
Faecalibacterium
Megamonas

Revision editor(s): Ufuoma Ejite

Signature 2

Needs review

Curated date: 2023/03/15

Curator: Ufuoma Ejite

Revision editor(s): Ufuoma Ejite

Source: Figure 1a

Description: Differences of phylogenetic abundance between AS patients and healthy controls

Abundance in Group 1: decreased abundance in Ankylosing spondylitis patients

NCBI Links
Eubacterium
Parabacteroides
Roseburia

Revision editor(s): Ufuoma Ejite